Literature DB >> 2151368

Hormone dependence of a mouse mammary tumor line induced in vivo by medroxyprogesterone acetate.

E Kordon1, C Lanari, R Meiss, P Elizalde, E Charreau, C Dosne Pasqualini.   

Abstract

The administration of MPA to virgin female BALB/c mice led to the development of mammary adenocarcinomas, which in further in vivo transplants gave rise to both MPA-dependent and MPA-independent lines. In this paper we chose one of the MPA-dependent lines with high contents of estrogen (ER) and progesterone (PR) receptors, and were able to demonstrate that a) the growth of these tumors could be manipulated by the administration or the withdrawal of the hormonal supply; b) PR were down-regulated in MPA-treated mice; c) progesterone had the same stimulatory effect as MPA on tumor growth; d) tumors did not grow in estrogen-treated mice; e) tumor growth was much lower in males than in females; f) the presence of the ovaries had a positive influence on tumor growth, even in the presence of MPA; g) the withdrawal of progestin pellets in ovariectomized mice usually led to complete remissions followed by regrowth of the tumors after several weeks; and h) the regrowing tumors maintained their steroid receptor pattern and (in 3 out of 4 cases) their hormone-dependent behavior in further passages.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2151368     DOI: 10.1007/bf01812682

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  31 in total

1.  Induction of mammary adenocarcinomas by medroxyprogesterone acetate in BALB/c female mice.

Authors:  C Lanari; A A Molinolo; C D Pasqualini
Journal:  Cancer Lett       Date:  1986-11       Impact factor: 8.679

2.  Specific estrogen binding by the cytoplasm fof human breast carcinoma.

Authors:  S G Korenman; B A Dukes
Journal:  J Clin Endocrinol Metab       Date:  1970-05       Impact factor: 5.958

3.  Classification of mouse mammary tumors in Dunn's miscellaneous group including recently reported types.

Authors:  B Sass; T B Dunn
Journal:  J Natl Cancer Inst       Date:  1979-05       Impact factor: 13.506

4.  Prolactin and murine mammary tumorigenesis: a review.

Authors:  C W Welsch; H Nagasawa
Journal:  Cancer Res       Date:  1977-04       Impact factor: 12.701

5.  Evidence for the involvement of the submandibular gland epidermal growth factor in mouse mammary tumorigenesis.

Authors:  H Kurachi; S Okamoto; T Oka
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

Review 6.  Evaluation of effects of sexual steroids on the hypothalamic-pituitary system of animals and man.

Authors:  M F El Etreby; K J Gräf; P Günzel; F Neumann
Journal:  Arch Toxicol Suppl       Date:  1979

7.  Mammary tumors and serum hormones in the bitch treated with medroxyprogesterone acetate or progesterone for four years.

Authors:  D W Frank; K T Kirton; T E Murchison; W J Quinlan; M E Coleman; T J Gilbertson; E S Feenstra; F A Kimball
Journal:  Fertil Steril       Date:  1979-03       Impact factor: 7.329

8.  Adrenal steroids stimulate growth and progesterone receptor levels in rat uterus and DMBA-induced mammary tumors.

Authors:  P G Spinola; B Marchetti; F Labrie
Journal:  Breast Cancer Res Treat       Date:  1986       Impact factor: 4.872

Review 9.  Differentiation of the mammary gland and susceptibility to carcinogenesis.

Authors:  J Russo; L K Tay; I H Russo
Journal:  Breast Cancer Res Treat       Date:  1982       Impact factor: 4.872

10.  Medroxyprogesterone acetate enhances spontaneous mammary tumorigenesis and uterine adenomyosis in mice.

Authors:  H Nagasawa; M Aoki; N Sakagami; M Ishida
Journal:  Breast Cancer Res Treat       Date:  1988-09       Impact factor: 4.872

View more
  10 in total

Review 1.  Therapy for menopausal symptoms during and after treatment for breast cancer : safety considerations.

Authors:  Rodney Baber; Martha Hickey; Michelle Kwik
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 2.  Progesterone regulation of stem and progenitor cells in normal and malignant breast.

Authors:  Sunshine Daddario Axlund; Carol A Sartorius
Journal:  Mol Cell Endocrinol       Date:  2011-09-16       Impact factor: 4.102

3.  The effects of intermittent progesterone upon tamoxifen inhibition of tumor growth in the 7,12-dimethylbenzanthracene rat mammary tumor model.

Authors:  D F Gibson; D A Johnson; S M Langan-Fahey; M K Lababidi; W H Wolberg; V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1993-09       Impact factor: 4.872

4.  Effect of medroxyprogesterone acetate (MPA) and serum factors on cell proliferation in primary cultures of an MPA-induced mammary adenocarcinoma.

Authors:  G Dran; I A Luthy; A A Molinolo; F Montecchia; E H Charreau; C D Pasqualini; C Lanari
Journal:  Breast Cancer Res Treat       Date:  1995-08       Impact factor: 4.872

Review 5.  MMTV-induced pregnancy-dependent mammary tumors : early history and new perspectives.

Authors:  Edith C Kordon
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-07-26       Impact factor: 2.673

6.  Progesterone induction of mammary carcinomas in BALB/c female mice. Correlation between progestin dependence and morphology.

Authors:  E C Kordon; A A Molinolo; C D Pasqualini; E H Charreau; P Pazos; G Dran; C Lanari
Journal:  Breast Cancer Res Treat       Date:  1993-10       Impact factor: 4.872

7.  Antisense oligonucleotides targeting the progesterone receptor inhibit hormone-independent breast cancer growth in mice.

Authors:  Caroline A Lamb; Luisa A Helguero; Sebastián Giulianelli; Rocío Soldati; Silvia I Vanzulli; Alfredo Molinolo; Claudia Lanari
Journal:  Breast Cancer Res       Date:  2005-11-09       Impact factor: 6.466

8.  Progesterone receptor activation downregulates GATA3 by transcriptional repression and increased protein turnover promoting breast tumor growth.

Authors:  Franco Izzo; Florencia Mercogliano; Leandro Venturutti; Mercedes Tkach; Gloria Inurrigarro; Roxana Schillaci; Leandro Cerchietti; Patricia V Elizalde; Cecilia J Proietti
Journal:  Breast Cancer Res       Date:  2014-12-06       Impact factor: 6.466

9.  Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development.

Authors:  Martin A Rivas; Leandro Venturutti; Yi-Wen Huang; Roxana Schillaci; Tim Hui-Ming Huang; Patricia V Elizalde
Journal:  Breast Cancer Res       Date:  2012-05-14       Impact factor: 6.466

10.  Progesterone receptor assembly of a transcriptional complex along with activator protein 1, signal transducer and activator of transcription 3 and ErbB-2 governs breast cancer growth and predicts response to endocrine therapy.

Authors:  María C Díaz Flaqué; Natalia M Galigniana; Wendy Béguelin; Rocío Vicario; Cecilia J Proietti; Rosalía Russo; Martín A Rivas; Mercedes Tkach; Pablo Guzmán; Juan C Roa; Esteban Maronna; Viviana Pineda; Sergio Muñoz; María Mercogliano; Eduardo H Charreau; Patricio Yankilevich; Roxana Schillaci; Patricia V Elizalde
Journal:  Breast Cancer Res       Date:  2013-12-17       Impact factor: 6.466

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.